Pembrolizumab (Keytruda?) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti-tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. BioSim? Pembrolizumab ELISA kit has been developed for specific quantification of Pembrolizumab concentration in human serum or plasma with high sensitivity and reproducibility.
產(chǎn)品特點(diǎn)
? Easy, convenient, sensitive and time-saving method to measure the level of Pembrolizumab in human serum and plasma.
? Detection Range: 30 - 1000 ng/ml
? Sensitivity: 10 ng/ml
? Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
? Recovery rate: 85 – 115% with normal human serum samples with known concentrations
? Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade?), adalimumab (Humira?) , etanercept (Enbrel?), bevacizumab (Avastin?) and trastuzumab (Herceptin?)